Compare
The details that actually shape the buying decision.
Evidence, risk, regulatory flags, cost, and vendor coverage — side by side, without affiliate spin.
01· Subject
DSIP
Sleep-related peptide with human IV infusion studies showing sleep pressure effects. Mechanism uncertain.
Tier Bmed-high risk
02· Subject
Hexarelin
GHRP-class secretagogue with stronger GH stimulation and studied sleep-endocrine effects.
Tier B-Chigh risk
01 · At a glance
| Decision factor | DSIP | Hexarelin | Semax |
|---|---|---|---|
| Primary fit | sleep & relaxation and anxiety & mood comparisons | muscle growth & strength and sleep & relaxation comparisons | cognitive & neuroprotection and anxiety & mood comparisons |
| Evidence | Tier B | Tier B-C | Tier B-C |
| Risk | med-high | high | med-high |
| Experience level | intermediate | advanced | intermediate |
| Budget tier | mid | mid | mid |
| Administration route | intravenous, subcutaneous | subcutaneous, intravenous | intranasal |
02 · Use case & timing
| Decision factor | DSIP | Hexarelin | Semax |
|---|---|---|---|
| Goal fit | Sleep & Relaxation, Anxiety & Mood | Muscle Growth & Strength, Sleep & Relaxation, GH Axis Optimization | Cognitive & Neuroprotection, Anxiety & Mood |
| What users compare it for | Sleep pressure effects in some human studies; outcomes inconsistent across trials. | GH-axis modulation; sleep architecture research interest. | Neurotrophic signaling; cognitive/neuroprotection narratives from Russian/EE clinical literature. |
| Onset timeline | Acute subjective effects reported after dosing; sleep architecture outcomes assessed same day/night. | Acute endocrine effects; sleep effects studied overnight. | Gene expression changes within hours (animal); clinical stroke outcomes are longer-horizon. |
| Main tradeoff | Evidence is stronger than most compounds in this category, but route, side effects, and vendor fit still matter. | Potential upside comes with much more safety and screening caution than lower-risk alternatives. | Evidence and product availability can still be uneven, so documentation matters more than hype. |
03 · Safety & restrictions
| Decision factor | DSIP | Hexarelin | Semax |
|---|---|---|---|
| Adverse effects | Limited modern safety data; moderate uncertainty. | Endocrine spillover (ACTH, cortisol, prolactin). | Immunogenicity/impurity concerns (FDA); limited Western safety framing. |
| Contraindications | No established label. | No formal label. | No established label. |
| Interaction notes | Unknown; avoid polypharmacy recommendations. | Unknown; caution with other GH-axis compounds. | Unknown; avoid claiming synergy with SSRIs/benzodiazepines without data. |
| Regulatory status | Not approved | Not approved | Not approved |
| FDA flag | FDA status unclear | FDA status unclear | FDA compounding caution |
| WADA status | Not listed | WADA S2 | Status unclear |
04 · Age & monitoring
| Decision factor | DSIP | Hexarelin | Semax |
|---|---|---|---|
| Supported age ranges | No age guidance yet | No age guidance yet | 25-34, 35-44, 45-54, 55-64, 65+ |
| Life-stage note | Not yet documented | Not yet documented | Usually discussed for adult cognitive or recovery support rather than youth-oriented performance enhancement. |
| Monitoring burden | Not specified | Not specified | Not specified |
| Follow-up cadence | Not yet documented | Not yet documented | Not yet documented |
05 · Cost & sourcing
| Decision factor | DSIP | Hexarelin | Semax |
|---|---|---|---|
| Typical cycle cost | €8.02 | No reliable estimate yet | €13.76 |
| Estimated monthly cost | €16.05 | No reliable estimate yet | €27.52 |
| Cost confidence | High confidence | No estimate | High confidence |
06 · Before you buy
| Decision factor | DSIP | Hexarelin | Semax |
|---|---|---|---|
| Tracked vendor listings | 3 listings | 0 listings | 3 listings |
| Sourcing note | Product format varies by listing, so double-check route, concentration, and presentation. | No tracked product page yet, so sourcing takes more manual review. | Product format varies by listing, so double-check route, concentration, and presentation. |
| Stack-friendly? | Usually stack-friendly | Usually stack-friendly | Usually stack-friendly |
Still deciding
Get a plan tailored to you.
Side-by-side narrows the field. The quiz factors in your goal, experience, and risk tolerance to surface a starting compound and dosing range.